Galapagos FIRST LOOK: Progress on BD with BridGene preclinical collaboration
Galapagos announced that it has entered into a preclinical collaboration with BridGene to discover novel small molecule drug candidates in oncology for $27m upfront and $700m in milestones, plus single digit tiered royalties. While considered early stage, this collaboration is a sign of progress on the BD front, and we'd be keen to see more on this in the coming quarters. We see this collaboration as a good fit for Galapagos given the company's expertise in small molecules, and are keen to learn about timelines for when candidates from this program are expected to enter the clinic. We reiterate our Accumulate rating and €55 TP.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.